Clinical Research Enrolling
| Disease | Research Study | Main I/E | Study Type | CT.gov Link | PI | Primary Coordinator | PC Number | Back-Up Coordinator | BC Number |
|---|---|---|---|---|---|---|---|---|---|
| GN - all types | GDCN Registry | Kidney disease, healthy controls, disease controls | Registry, Biobank | NA | Falk | candace_henderson@med.unc.edu | 919-445-2623 | lmccabe@email.unc.edu | 919-445-2635 |
| Monoclonal Gammopathy | Registry of MGRS | All monoclonal gammopathy with renal involvment | Registry | NA | Hladik | anne_froment@med.unc.edu | 919-445-2622 | jordano@med.unc.edu | 919-445-2672 |
| ANCA | Pathobiology of ANCA | New or flaring ANCA | Translational | NA | Falk | candace_henderson@med.unc.edu | 919-445-2623 | kristin_brock@med.unc.edu | 919-445-2730 |
| ANCA | CD5 WATCH (B cell recovery) | 1 month in remission (after 1st treatment or 1st relapse in AAV) | Device | NCT03906227 | Derebail | sandy_grubbs@med.unc.edu | 919-445-2658 | anne_froment@med.unc.edu | 919-445-2622 |
| ANCA | Lung function in ANCA Vasculitis patients | all AAV having done or willing to do a spirometry test | Observational | NA | Henderson | anne_froment@med.unc.edu | 919-445-2622 | emmie_cole@med.unc.edu | 919-445-2627 |
| MN | REBOOT (belimumab and rituximab) | primary MN biopsied in last 3 years; age 18-75; eGFR > 40; proteinuria > 4g/day; BP < 140/90 | Phase 2 | NCT03949855 | Derebail | anne_froment@med.unc.edu | 919-445-2622 | ||
| MN, MCD, FSGS | NEPTUNE ( Nephrotic Syndrome Study Network) | Must be enrolled PRE BIOPSY; UPCR≥1.5 | Observational; Biobank | NCT01209000 | Derebail/Gibson (Peds) | jordano@med.unc.edu | 919-445-2672 | sandy_grubbs@med.unc.edu | 919-445-2658 |
| MN, MCD, FSGS, IgA | CureGN (Cure Glomerulonephropathy Network) | Biopsied in the last 5 years; no diabetes at the time of biopsy | Observational; Biobank | NA | Mottl | maggie_dangelo@med.unc.edu | 919-445-2682 | caroline_poulton@unc.edu | 919-445-2636 |
| FSGS | PODO (PF-06730512) | 18-70 yo- Primary FSGS, eGFR> 45; UPCR> 1.5 | Phase 2 | NCT03448692 | Mottl | anne_froment@med.unc.edu | 919-445-2622 | emmie_cole@med.unc.edu | 919-445-2627 |
| FSGS | LIPOSORBER LA-15 | Primary FSGS, up to75 yo, when weight is >15kg and eGFR> 45 & standard treatment unsuccessful OR patient is post-transplant | Device | NCT02235857 | Jain | anne_froment@med.unc.edu | 919-445-2622 | ||
| IGAN | enVISion (VIS649) | >=18yo; IgAN, eGFR> 44; UPCR> 0.75- no T1 diabetes. Controlled T2 OK. On max ACEi or ARB. Not on steroid for at least 8 weeks. | Phase 2 | NCT04287985 | Jain | anne_froment@med.unc.edu | 919-445-2622 | jordano@med.unc.edu | 919-445-2672 |
| IGAN | Ravulizumab IV for IgAN | age 18-75; primary, rapidly progressive IgAN; eGFR <30; proteinuria > 1gm, uncontrolled HTN, no immunosuppression in last 6 months | Phase 2 | NCT04564339 | Mottl | anne_froment@med.unc.edu | 919-445-2622 | ||
| LUPUS | MiSLE - Mesenchymal Stem Cells for refractory lupus | BILAG A or B, Sledai score > 5, completed 6 months induction therapy | Phase 2 | NCT02633163 | Sheikh | sandy_grubbs@med.unc.edu | 919-445-2658 | julie_walker@med.unc.edu | |
| LUPUS | Ravulizumab IV for lupus nephritis | age 18-75; clinically active LN Class III or IV; eGFR <30; proteinuria > 1gm, uncontrolled HTN | Phase 2 | NCT04564339 | Mottl | anne_froment@med.unc.edu | 919-445-2622 | ||
| DKD | TRIDENT | Diabetes, >= 18yo, getting a biopsy: must be enrolled PRE-BIOPSY | Observational; Biobank | NCT02986984 | Mottl | jordan_ormondfoster@med.unc.edu | 919-445-2672 | anne_froment@med.unc.edu | 919-445-2622 |
| Undergoing CEUS | Contrast Enhanced Ultrasound of the Kidneys Registry | Patients undergoing CEUS | Registry | NA | Chang | emmie_cole@med.unc.edu | 919-445-2627 | anne_froment@med.unc.edu | 919-445-2622 |
| In-patient dialysis | PLUS-HD | in-patient dialysis | Observational | NA | Chang | julia3@email.unc.edu | 919-445-2686 | jordano@med.unc.edu | 919-445-2672 |
Contact by phone: Emmie Cole 5-2627, Maggie D’Angelo 919-445-2682, Anne Froment 5-2622 , Sandy Grubbs 5-2658, Candace Henderson 5-2623 , Jordan Ormond Foster 5-2672; Julia Narendra 5-2686, Caroline Poulton 5-2636, Matthew Tugman 5-2699